Strategies under investigation for targeting LSCs
| LSC antigen . | Description . | Antibody, if applicable . | Active and recruiting trials . |
|---|---|---|---|
| CD123 | IL-3 receptor α chain23,24 | SGN-123A, antibody–drug conjugate | NCT02848248 |
| JNJ-56022473, dual-specific antibody with CD16 | NCT02472145 | ||
| SL-401, antibody toxin chimeric protein using diphtheria toxin | NCT02113982 | ||
| NCT02270463 | |||
| XmAb14045, dual-specific antibody with CD3 | NCT02730312 | ||
| MGD006, dual-specific antibody with CD3 | NCT02152956 | ||
| KHK2823, IgG1 antibody | NCT02181699 | ||
| CLL-1 | C-type lectin-like molecule-125 | ||
| CD33 | Receptor of myeloid cells, member of the Ig superfamily26 | SGN-CD33A, antibody–drug conjugate | NCT02326584 |
| NCT02785900 | |||
| NCT02312037 | |||
| NCT02614560 | |||
| IMGN779, antibody drug conjugate | NCT02674763 | ||
| Gemtuzumab ozogamicin, antibody–drug conjugate | NCT01869803 | ||
| CD44 | Receptor for hyaluronic acid27,28 | ||
| CD47 | Receptor for signal regulatory protein α (SIRPα)29,30 | Hu5F9-G4, anti-CD47 monoclonal antibody | NCT02678338 |
| TTI-621, antibody against CD47 binding domain of SIRPα | NCT02663518 | ||
| INBRX-103 (CC-90002), anti-CD47 monoclonal antibody | NCT02367196 | ||
| NCT02641002 | |||
| CD96 | Tactile, member of Ig superfamily31 | ||
| CD93 | Marker of a nonquiescent LSC population in MLL-rearranged AML11 | ||
| CD25 | IL-2 receptor α chain32 | ADCT-301, antibody–drug conjugate | NCT02588092 |
| LMB-2, antibody toxin chimeric protein using Pseudomonas exotoxin | N/A for AML | ||
| CD32 | Fc-γ receptor II32 | ||
| Tim-3 | T-cell immunoglobulin mucin-333,34 | TSR-022, monoclonal antibody | N/A for AML |
| CD99 | MIC2 or single-chain type-1 glycoprotein (in press) | ||
| IL1-RAP | IL-1 receptor accessory protein35,36 | IL-1 receptor antagonist | N/A for AML |
| LSC antigen . | Description . | Antibody, if applicable . | Active and recruiting trials . |
|---|---|---|---|
| CD123 | IL-3 receptor α chain23,24 | SGN-123A, antibody–drug conjugate | NCT02848248 |
| JNJ-56022473, dual-specific antibody with CD16 | NCT02472145 | ||
| SL-401, antibody toxin chimeric protein using diphtheria toxin | NCT02113982 | ||
| NCT02270463 | |||
| XmAb14045, dual-specific antibody with CD3 | NCT02730312 | ||
| MGD006, dual-specific antibody with CD3 | NCT02152956 | ||
| KHK2823, IgG1 antibody | NCT02181699 | ||
| CLL-1 | C-type lectin-like molecule-125 | ||
| CD33 | Receptor of myeloid cells, member of the Ig superfamily26 | SGN-CD33A, antibody–drug conjugate | NCT02326584 |
| NCT02785900 | |||
| NCT02312037 | |||
| NCT02614560 | |||
| IMGN779, antibody drug conjugate | NCT02674763 | ||
| Gemtuzumab ozogamicin, antibody–drug conjugate | NCT01869803 | ||
| CD44 | Receptor for hyaluronic acid27,28 | ||
| CD47 | Receptor for signal regulatory protein α (SIRPα)29,30 | Hu5F9-G4, anti-CD47 monoclonal antibody | NCT02678338 |
| TTI-621, antibody against CD47 binding domain of SIRPα | NCT02663518 | ||
| INBRX-103 (CC-90002), anti-CD47 monoclonal antibody | NCT02367196 | ||
| NCT02641002 | |||
| CD96 | Tactile, member of Ig superfamily31 | ||
| CD93 | Marker of a nonquiescent LSC population in MLL-rearranged AML11 | ||
| CD25 | IL-2 receptor α chain32 | ADCT-301, antibody–drug conjugate | NCT02588092 |
| LMB-2, antibody toxin chimeric protein using Pseudomonas exotoxin | N/A for AML | ||
| CD32 | Fc-γ receptor II32 | ||
| Tim-3 | T-cell immunoglobulin mucin-333,34 | TSR-022, monoclonal antibody | N/A for AML |
| CD99 | MIC2 or single-chain type-1 glycoprotein (in press) | ||
| IL1-RAP | IL-1 receptor accessory protein35,36 | IL-1 receptor antagonist | N/A for AML |
Ig, immunoglobulin; IL, interleukin; N/A, not applicable.